Measuring HIV drug resistance in Nigerian children on dolutegravir to help create a rapid test
Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientists
This project looks for HIV integrase drug resistance in Nigerian children whose dolutegravir treatment is failing and aims to develop a quick test to detect it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11262275 on NIH RePORTER |
What this research studies
If your child joins, researchers will collect blood samples from children in Nigeria who have detectable virus despite being on dolutegravir. Lab teams will sequence the virus to quantify integrase resistance mutations and analyze how often these arise. The resistance data will be used with Nigerian collaborators to design and validate a rapid diagnostic that could detect these mutations at the point of care. Findings will also inform national surveys and treatment guidelines to help doctors pick effective medicines.
Who could benefit from this research
Good fit: Ideal candidates are children in Nigeria who are on dolutegravir but have detectable HIV viral load suggesting treatment failure.
Not a fit: Children who are virally suppressed on dolutegravir or people not taking dolutegravir are unlikely to gain direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to a rapid test that quickly identifies dolutegravir resistance so children can be switched to effective medicines sooner.
How similar studies have performed: Some adult studies (e.g., in Malawi) have found integrase resistance after dolutegravir failure, but pediatric data are scarce and rapid diagnostics for integrase resistance remain novel.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Rawizza, Holly Elizabeth — Brigham and Women's Hospital
- Study coordinator: Rawizza, Holly Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.